PrimeVax Immuno-Oncology to Present at Biocom Global Life Science Partnering Conference
SAN DIEGO, Feb. 22, 2017 /PRNewswire/ -- PrimeVax Immuno-Oncology, Inc. announced today its CEO, Tony Chen, will be presenting at the Annual Biocom Global Life Science Partnering Conference. The presentation will take place on March 2, at 11:15 AM, at the Torrey Pines Lodge, in San Diego.
"We are thankful to the organizers at Biocom who have chosen our company, amongst numerous others, to present at this international symposium of biotechnology companies, investors, and clinical researchers," said Mr. Chen. "In contrast to conferences in previous years, there is an increase in the number of cancer immunotherapy companies presenting. This trend reflects the excitement we observe in the industry where new methods are being tried to fight cancer."
PrimeVax takes a unique approach to treating cancer by combining virus-induced immune stimulation and dendritic cell therapy. A description of the PrimeVax approach was recently published in the peer-reviewed literature by the company management1.
"With the clinical implementation of various immunotherapeutic strategies, it is becoming more and more apparent that we need to activate multiple arms of the immune system at the same time," said Santosh Kesari, MD, PhD, Scientific Co-Founder of PrimeVax and Chair of Neurosciences and Neurotherapeutics at the John Wayne Cancer Institute and Pacific Neuroscience Institute. "We are very excited about the progress that Mr. Chen has made in advancing this technology, and I look forward to helping patients suffering from deadly cancers such as melanoma and glioblastoma."
PrimeVax Immuno-Oncology, Inc. is focused on development of personalized immunotherapy by leveraging its PV-001 platform. The platform enables PrimeVax to develop a 1 time 1 week cancer treatment schedule for many cancer types agnostic of tumor mutation characteristics. PV-001 leverages the body's innate and adaptive immune responses simultaneously to trigger activation of T cells, NK cells, and other immunotherapeutic effects. The Company was founded in 2015 and will engage in human clinical trials in 2017. Initial indications to be targeted are metastatic melanoma, triple negative breast cancer, and glioblastoma.
Contact: PrimeVax Immuno-Oncology, Inc. Tony Chen CEO Tony.Chen@PrimeVax.com PrimeVax Immuno-Oncology
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/primevax-immuno-oncology-to-present-at-biocom-global-life-science-partnering-conference-300411608.html
SOURCE PrimeVax Immuno-Oncology, Inc.